We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

ModiQuest Research and Cellectis to Collaborate

Read time: Less than a minute

ModiQuest Research BV has announced that it has entered into a collaboration with Cellectis aimed at the generation of novel monoclonal antibodies against Cellectis’ target(s).

During the collaboration, ModiQuest may make use of its proprietary electrofusion technology, ModiFuse™. Financial details of the collaboration were not disclosed.

“We are pleased that Cellectis has selected ModiQuest Research as a development partner for its activities,” said Dr. Jos Raats, Managing Director of ModiQuest Research. “This collaboration once more demonstrates the value of our broad and unique antibody generation platform and we are delighted to work together with Cellectis in the emerging field of cancer immunotherapy.”

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.